ANNOVIS BIO (ANVS)

ANVS Stock Earnings: Annovis Bio Misses EPS for Q4 2023

ANVS stock results show that Annovis Bio missed analyst estimates for earnings per share the fourth quarter of 2023.

ANVS Stock Earnings: Annovis Bio Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Annovis Bio (NYSE:ANVS) just reported results for the fourth quarter of 2023.An...

Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company...

Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans

Further look at earlier Phase 1b study by ADCS unveils confirmatory data MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:...

Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease

MALVERN, Pa., March 20, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for...

Sell Signal: 3 Stocks to Unload Before the Bubble Bursts

It's time to offload stocks in the automotive, aerospace, and biotech sectors due to emerging financial and operational risks.

Annovis Bio falls after Brookline Capital downgrades on PD trial complications (NYSE:ANVS)

Orbon Alija/E+ via Getty Images Annovis Bio (NYSE:ANVS) shares fell in early trade on Wednesday after Brookline Capital Markets downgraded the company’s...

Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease

MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for...

3 Growth Stocks to Sell in February Before They Bottom

Discover why these growth stocks to sell are facing adversities in automotive retail, aerospace, defense and biotechnology.

Annovis Bio files for $250M mixed shelf (NYSE:ANVS)

Annovis Bio files prospectus for a proposed mixed shelf offering of up to $250M, as per SEC filing.

Annovis falls 16% on Phase 3 data delay for Parkinson's drug (NYSE:ANVS)

Shares of Annovis Bio (ANVS) tumbled 16% in morning trading Wednesday after the company said the release of Phase 3 data for its Parkinson’s disease drug candid

Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement

MALVERN, Pa., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for...

Annovis Bio to Participate in the 139th Yale CEO Summit

BERWYN, Pa., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for...

Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease

BERWYN, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for...

Annovis Bio Appoints Andrew Walsh as Vice President Finance

BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for...

Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections

BERWYN, Pa., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing neurodegenerative...

Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update

BERWYN, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative...

Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients

Annovis Bio shares fall after pricing units offering at discount (NYSE:ANVS)

Annovis Bio (ANVS) announces a $7.5 million public offering of units. Each unit includes one share of common stock and a warrant to purchase one share.

Annovis Bio Announces Pricing of $7.5 Million Public Offering

Annovis Alzheimer's study gets green light from safety monitors (ANVS)

Annovis Bio (ANVS) received a positive recommendation from safety monitors for its Phase 2/3 study of buntanetap in the treatment of mild-to-moderate Alzheimer's disease.

Annovis Bio announces launch of proposed public offering (NYSE:ANVS)

Annovis Bio announces proposed public offering, offering common stock and warrant for purchase, to fund drug development and general purposes.

Annovis Bio Announces Launch of Proposed Public Offering